reference/16742740

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16742740

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Research Support, Non-U.S. Gov't
endingPage	1015
issn	1432-0843 0344-5704
issueIdentifier	5
pageRange	1007-1015
publicationName	Cancer Chemotherapy and Pharmacology
startingPage	1007
bibliographicCitation	Aogi K, Yoshida M, Sagara Y, Kamigaki S, Okazaki M, Funai J, Fujimoto T, Toi M, Saeki T, Takashima S. The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype. Cancer Chemother Pharmacol. 2011 May;67(5):1007–15. doi: 10.1007/s00280-010-1390-1. PMID: 20628744.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_719cce4027cac47a86980508cdece263 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2c945429ea51b4ecb411b0e7110a942a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e4379f01c15cda7bc925e1a7b0da008a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e3dd0bd284d5b2b2b9341505b8170e72 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5f6a7812a04c986b0aea9d697b911013 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6a147610dd0fe7856e17a5b8bd32b423 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c3cddc3019ef8c3dd562940d68707c9d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_44e0ca6e485ec334a47e1d6d63204d83 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_37ac30e3fa6af85e1cea42472a029604 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_87f9939016abb1f392ee549aeaa99c73
date	2010-07-14^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1007/s00280-010-1390-1 https://pubmed.ncbi.nlm.nih.gov/20628744
isPartOf	https://portal.issn.org/resource/ISSN/1432-0843 https://portal.issn.org/resource/ISSN/0344-5704 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2664
language	English
source	https://scigraph.springernature.com/ https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype
discusses	http://id.nlm.nih.gov/mesh/M000754277 http://id.nlm.nih.gov/mesh/M0005997 http://id.nlm.nih.gov/mesh/M0028048 http://id.nlm.nih.gov/mesh/M0495206 http://id.nlm.nih.gov/mesh/M0026156
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D001943Q000188 http://id.nlm.nih.gov/mesh/D009376Q000188 http://id.nlm.nih.gov/mesh/D018719Q000096 http://id.nlm.nih.gov/mesh/D000971Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D053208 http://id.nlm.nih.gov/mesh/D001943Q000473 http://id.nlm.nih.gov/mesh/D001943Q000235 http://id.nlm.nih.gov/mesh/D010641 http://id.nlm.nih.gov/mesh/D009376Q000473 http://id.nlm.nih.gov/mesh/D000093542 http://id.nlm.nih.gov/mesh/D003841Q000008 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D003841Q000031 http://id.nlm.nih.gov/mesh/D017239Q000008 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D018719Q000235 http://id.nlm.nih.gov/mesh/D009362 http://id.nlm.nih.gov/mesh/D009376Q000235
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8321 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7ed75134b36b0e173fb44798462e4e66 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9d7fe60f25abdf582afc7cdca238bde8

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129221764 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127639621

Showing number of triples: 1 to 66 of 66.